Azitra (AZTR) Change in Receivables (2022 - 2026)
Azitra's (AZTR) quarterly Change in Receivables came in at $4196.0 in Q1 2026, up 1900.86% YoY from $209.71 in Q1 2025, and up 360.09% on a QoQ basis from $912.0 in Q4 2025.
Azitra (AZTR) Change in Receivables (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Change in Receivables data on file, last reported at $4196.0 in Q1 2026.
- Quarterly Change in Receivables rose 1900.86% year-over-year to $4196.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5108.0 (up 375.07% YoY) and the FY2025 annual result came in at $679.0, up 100.69% from the prior year.
- Change in Receivables advanced to $4196.0 in Q1 2026, from $912.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $347731.0 in Q2 2023 to a low of -$445120.0 in Q3 2023.
- A 5-year average of -$1612.2 and a median of $233.0 in 2024 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables slumped 846.49% — and 2026, when it jumped 1900.86%.
- Tracing AZTR's Change in Receivables over 5 years: stood at $97125.0 in 2022, then gained by 1.16% to $98255.0 in 2023, then tumbled by 99.76% to $233.0 in 2024, then soared by 291.42% to $912.0 in 2025, then soared by 360.09% to $4196.0 in 2026.
- The last three Change in Receivables figures came in at $4196.0 (Q1 2026), $912.0 (Q4 2025), and -$233.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -4,199.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,199.00 |
| Jun 30, 2026 | -4,199.00 |
| Mar 31, 2026 | 4,196.00 |
| Mar 31, 2026 | 4,196.00 |
| Dec 31, 2025 | 912.00 |
| Dec 31, 2025 | 912.00 |
| Mar 31, 2025 | -233.00 |
| Mar 31, 2025 | -233.00 |
| Dec 31, 2024 | 233.00 |
| Dec 31, 2024 | 233.00 |
| Sep 30, 2024 | -1,125.00 |
| Sep 30, 2024 | -1,125.00 |
| Jun 30, 2024 | -732.00 |
| Jun 30, 2024 | -732.00 |
| Mar 31, 2024 | -96,398.00 |
| Mar 31, 2024 | -96,398.00 |
| Dec 31, 2023 | 98,255.00 |
| Dec 31, 2023 | 98,255.00 |
| Sep 30, 2023 | -445,120.00 |
| Sep 30, 2023 | -445,120.00 |